Either they P&D big time or they have some of the worst investment picks I've seen. Examples: AAPL, PKD, TC, MUX, DVN, DDD, and so many others. All I know is I had several stocks they pumped like crazy, only to have them crater after earnings. Schwab told me there investment analysis is more long term. They said a year. I called them back in a year and told them there information was a failure last year and even worse now.
Motley fools is not trying to tell us anything about cyto. They are alwasy trying to sell their service. You will notice they often mention two or three widely held companies in the article so that it appears in the news of those comapnies too All the coverage seems sponsored.
I see CYTK making a paragraph on next weeks highlights MF as a positive development, we are alongside some here nice companies in that article. Also, if readers check out the pipeline they will be surprised to see that there is more diversity than stated. There are other drugs besides MO, and with near term catalysts. Another buying opportunity for CYTK with a lower SP around CC is very attractive. I haven't sold a share yet.